402 related articles for article (PubMed ID: 17699449)
1. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
2. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
[TBL] [Abstract][Full Text] [Related]
5. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
8. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
11. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
12. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation.
Petrakis I; Stylianou K; Mavroeidi V; Vardaki E; Stratigis S; Stratakis S; Xylouri I; Perakis C; Petraki C; Nakopoulou L; Daphnis E
Nephrol Dial Transplant; 2010 Jun; 25(6):2020-3. PubMed ID: 20133281
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
[TBL] [Abstract][Full Text] [Related]
14. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
[TBL] [Abstract][Full Text] [Related]
15. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation.
Weichman K; Dember LM; Prokaeva T; Wright DG; Quillen K; Rosenzweig M; Skinner M; Seldin DC; Sanchorawala V
Bone Marrow Transplant; 2006 Sep; 38(5):339-43. PubMed ID: 16862166
[TBL] [Abstract][Full Text] [Related]
17. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
[TBL] [Abstract][Full Text] [Related]
18. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
Snanoudj R; Mamzer-Bruneel MF; Hermine O; Grunfeld JP; Chauveau D
Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
[No Abstract] [Full Text] [Related]
19. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
20. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
